Published in Vaccine Weekly, May 24th, 1999
The simple structure of 2',6'-dihydroxy-4'-methoxychalcone (DMC) may enable it to serve as a new lead compound for the synthesis of novel antileishmanial drugs, reported Eduardo Caio Torres-Santos of Brazil's Universidade Federal do Rio de Janeiro and colleagues.
Torres-Santos et al. purified DMC from the dichloromethane extract of Piper aduncum (Piperaceae) inflorescences and described the selective effects of the active chalcone against Leishmania amazonensis (Piper aduncum on Leishmania...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.